Tango Therapeutics, Inc. beat EPS estimates 62% of the time across 16 reported quarters (10 beats, 6 misses), averaging +5.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.31 | $-0.37 | -19.4% | Miss | |
| Q1 FY26 | $-0.32 | $-0.32 | +0.0% | Beat | |
| Q4 FY25 | $-0.31 | $-0.29 | +6.5% | Beat | |
| Q3 FY25 | not reported | $0.13 | not reported | not reported | |
| Q2 FY25 | $-0.35 | $-0.35 | +0.0% | Beat | |
| Q1 FY25 | $-0.34 | $-0.36 | -5.9% | Miss | |
| Q4 FY24 | $-0.32 | $-0.35 | -9.4% | Miss | |
| Q3 FY24 | $-0.34 | $-0.27 | +20.6% | Beat | |
| Q2 FY24 | $-0.34 | $-0.24 | +29.4% | Beat | |
| Q1 FY24 | $-0.31 | $-0.35 | -12.9% | Miss | |
| Q4 FY23 | $-0.28 | $-0.32 | -14.3% | Miss | |
| Q3 FY23 | $-0.34 | $-0.23 | +32.4% | Beat |
Back to TNGX overview · TNGX holders · TNGX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.